ADA

VIDEO: Kieran Docherty, MBChB, discusses results of the DAPA-HF analysis on the impact of background T2D therapy on clinical outcomes in patients with T2D and HFrEF.

ADA 2020. Average A1c for a recent young cohort with type 2 diabetes was 8.5%, according to research presented at the ADA Virtual Scientific Sessions.

Physicians’ CKD awareness in T2D is linked with CKD severity, suggests a new study presented this week at the American Diabetes Association’s 80th Virtual Scientific Sessions.

VIDEO: Silvio Inzucchi, MD, discusses results of a prespecified analysis of the DAPA-HF trial, which found that dapagliflozin reduced new onset diabetes by 32% in patients with heart failure.

ADA 2020: Glycemic control was worse for black patients who experienced hurried interaction with healthcare providers than for those who did not, a new study reports.

ADA 2020. Improvement in glycemic control among US veterans was seen across 5 study sites and was sustained at 18 months after study initiation, says study reported at the ADA 80th Virtual Scientific Sessions.

ADA 2020. An investigational once-weekly insulin proved comparable in safety and efficacy to traditional once-daily insulin glargine in findings presented at the ADA 80th Annual Virtual Scientific Sessions.

ADA 2020. Dapagliflozin reduced new onset type 2 diabetes in patients with heart failure with reduced ejection fraction, according to a study released today at the ADA 80th Virtual Scientific Sessions.

ADA2020: Empagliflozin significantly, durably delays need for insulin and for large dose increases, in patients with type 2 diabetes and cardiovascular disease, finds study presented at ADA 80th Scientific Sessions.

ADA 2020: A new automatic insulin delivery system improves glycemic control in young people with type 1 diabetes, according to research presented at the American Diabetes Association Virtual Scientific Sessions.